MRKR Insider Trading
Insider Ownership Percentage: 14.50%
Insider Buying (Last 12 Months): $1,809,072.00
Insider Selling (Last 12 Months): $0.00
Marker Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at Marker Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Marker Therapeutics Share Price & Price History
Current Price: $1.18
Price Change: ▼ Price Decrease of -0.22 (-15.71%)
As of 03/13/2025 05:00 PM ET
Marker Therapeutics Insider Trading History
Marker Therapeutics Institutional Trading History
Data available starting January 2016
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Read More on Marker Therapeutics
Volume
157,849 shs
Average Volume
149,177 shs
Market Capitalization
$12.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.51
Who are the company insiders with the largest holdings of Marker Therapeutics?
Who are the major institutional investors of Marker Therapeutics?
Which major investors are buying Marker Therapeutics stock?
Within the last quarter, MRKR stock was acquired by institutional investors including:
- Alyeska Investment Group L.P.
- NEA Management Company LLC
- Blue Owl Capital Holdings LP
- LPL Financial LLC
- Northern Trust Corp
- Millennium Management LLC
- Aisling Capital Management LP
In the last year, these company insiders have bought Marker Therapeutics stock:
- Enterprise Associates 16 New (Major Shareholder)
- Steve Elms (Director)
- Norman David Eansor (Director)
Learn More investors buying Marker Therapeutics stock.